You need to enable JavaScript to run this app.
FDA defends Aduhelm's accelerated approval, while others call for reform
Regulatory News
Advertising, Promotion and Labeling
Biologics
Clinical Trials
Ethics
FDA meeting and communication strategy
North America
Pharmaceuticals
Regulatory Intelligence/Policy